September 4-7 2018
Boston, MA


Twitter logo for website footers 2

Posters and Late Breaking Abstracts

Designing the next generation Chimeric Antigen Receptors for Regulatory T cell therapy through in silico modeling-guided single chain Fv engineering.

Read here

A novel intracellular tumor antigen-targeted CAR-T therapy utilizing GITR signaling domain for enhanced therapeutic activity towards human solid tumors

Read here

Anti-GPC3 Chimeric Antigen Receptor Modified T cells (CAR-GPC3 T) in Chinese Patients with Refractory or Relapsed GPC3+ Hepatocellular Carcinoma (r/r GPC3+ HCC)

Read here

convertibleCAR-T cells provide in vivo dose control of activity with sequential and multiplex targeting

Read here

Amino acid substitutions yield high levels of TCR expression and target-specific T-cell activation: The Dominant TCR technology

Read here

Construction and Testing of a Humanized CD19-specific Chimeric Antigen Receptor (CAR) for the Treatment of B-cell malignancies

Read here

Advances with Switchable CAR-T Cells

Read here

A TCL1-specific TCR-based immunotherapy against B cell lymphoma

Read here

Dual-switch CAR-T cells: Orthogonal molecular switches to control activation and elimination of CAR-T cells to target CD123+ cancer

Read here